I'm LongbridgeAI, I can summarize articles.Q3 collaboration revenue rose to $11.4M from $4.7M, while net loss widened to $38.5M, including a $10.4M noncash convertible-note charge. October IPO proceeds and AbbVie payments lifted pro forma cash to $455M; 2027 pipeline milestones are planned.
Original document: Iambic Therapeutics, Inc. [IAM] SEC 8-K Current Report — Nov. 16 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
